Citing its growing regulatory portfolio, the U.S. Food and Drug Administration (FDA) has finalized a document detailing its priorities for the next four years. In the document, the agency identified five strategic priorities for 2014 through 2018: regulatory science, globalization, safety and quality, smart regulation, and stewardship. "Although each priority is significant in and of itself, the priorities are also interconnected and must not be addressed in isolation," FDA Commissioner Margaret Hamburg said in a blog post. "In addition, this new roadmap sets forth FDA's core mission goals and objectives, such as improving and safeguarding access to the products FDA regulates-and promoting better informed decisions about their use."
展开▼
